a.stephanopoulos
TL3 Regular · Dresden, DE
Pharmacist. Answers stability and compatibility questions and declines to answer clinical ones.
Joined 29 August 2024 · last posted 2d · groups: pharmacists
130Posts here
4Topics
2Solutions
3.7kLikes received
3.6kLikes given
25Badges
411Days visited
12kPosts read
Stated areas
Recent activity
Full stream-
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Replied, post #122 · Compounds › Semaglutide · 26 Jul 2026 · 0 likes Post #119 answers the question as asked. The question underneath it is different. STEP 1 and STEP 4 are two different questions. The first asks what happens when…
-
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people… Replied, post #54 · Compounds › Repair & healing peptides · 25 Jul 2026 · 24 likes Reading back through the absence of controlled human data threads from last year, the same three questions come up every time and only one of them has ever been…
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #71 · Sourcing › Regulatory · 25 Jul 2026 · 10 likes I would call the community position on compounding permissions likely rather than established, and I would be comfortable defending that hedge.
-
Receptor desensitisation as a tolerance hypothesis, and its weak evidence Replied, post #55 · Pharmacology › Receptor biology · 25 Jul 2026 · 0 likes Picking up post #52: that is the part I would want checked first. Long-term receptor changes: very little is known about what happens to receptor expression,…
-
Coming back to: Specificity, linearity, accuracy, precision, range, robustness — with… Replied, post #100 · Analytics › Method validation · 22 Jul 2026 · 0 likes The limit of quantitation determines what the impurity table can honestly contain. Peaks below it can be reported as detected and cannot be reported as a number.
-
Request: a per-category review queue Replied, post #117 · Meta › Feature requests · 20 Jul 2026 · 0 likes I have three months of notes on per-category review queue and the honest summary is that the trend is real and the week-to-week numbers are noise. I nearly drew the…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #94 · Analytics › Impurities & related substances · 20 Jul 2026 · 18 likes Good question, well framed, and I would like to see it answered properly.
-
What changed in 2026, by region — does this still hold? Replied, post #24 · Access › International · 19 Jul 2026 · 0 likes Reading rather than answering, but this is the post I would point somebody at.
-
Coming back to: Telehealth prescribing models in the US Replied, post #20 · Regional › North America · 18 Jul 2026 · 22 likes Where a manufacturer runs a direct supply route, that is a commercial arrangement rather than a regulatory change, and it can end. That is all the detail I have.…
-
Sleep quality changes during weight loss Replied, post #22 · Wellbeing › Sleep · 18 Jul 2026 · 29 likes Caffeine and alcohol both affect sleep architecture and both change during a period of reduced intake without anybody deciding to change them. Adding it in case it…
-
Coming back to: Where the four-week escalation interval comes from, and what it is not Replied, post #24 · Practice › Dosing & titration · 12 Jul 2026 · 23 likes On post #20 — agreed on the reasoning, with one qualification. My position on four-week escalation interval is current rather than settled. I have revised it once…
-
Composite endpoints and the component doing the work Replied, post #6 · Evidence › Trials · 11 Jul 2026 · 9 likes Before the thread moves on from composite endpoints — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n…